Multimodality imaging of thyroid-like follicular renal cell carcinoma with lung metastases, a new emerging tumor entity

2013 ◽  
Vol 39 (2) ◽  
pp. 388-393 ◽  
Author(s):  
R. A. Vicens ◽  
A. Balachandran ◽  
C. C. Guo ◽  
R. Vikram
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Lung Metastases ◽  
Multimodality Imaging ◽  
Tumor Entity

scholarly journals Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chao Liu ◽  
Jingjing Piao ◽  
Zhiyang Shang
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
General Condition ◽  
Renal Cell ◽  
Checkpoint Inhibitors ◽  
Lung Metastases ◽  
Left Lung ◽  
The Third ◽  
Bidirectional Regulation ◽  
Hyperprogressive Disease

Abstract Background Studies have shown that immune checkpoint inhibitors (ICIs) have limited efficacy and can even increase tumour burden in short time periods. This is usually called hyperprogressive disease (HPD). To date, there are few reports regarding HPD; fewer have analysed the relationship between HPD and radiotherapy combined with ICIs, and their conclusions are controversial. Case presentation A 42-year-old woman was diagnosed with stage IV renal clear cell carcinoma. The patient had previously received sorafenib and pazopanib as first- and second-line therapies, respectively. She received radiotherapy combined with nivolumab. Eighteen days after administration of the third dose of nivolumab, the patient’s general condition deteriorated; this was associated with immune-related adverse events. Computed tomography showed that the diameter of left lung metastases had sharply increased. A biopsy of the lung metastasis showed no infiltration of lymphocytes. The patient’s general condition worsened and she died of the disease on the 70th day after administration of the third dose of nivolumab. Conclusions This report describes the development of HPD following the administration of radiotherapy combined with ICIs in a case of advanced renal cell carcinoma. The case indicates that radiotherapy may show bidirectional regulation effects on anti-tumour immune response. If the immunosuppressive function of radiotherapy is dominant, combined with ICIs, it could result in HPD.

Immunotherapy for Lung Metastases of Murine Renal Cell Carcinoma

1999 ◽  
Vol 22 (4) ◽  
pp. 308-314 ◽  
Author(s):  
Nobuyasu Nishisaka ◽  
Atul Maini ◽  
Yoshihisa Kinoshita ◽  
Ryoji Yasumoto ◽  
Taketoshi Kishimoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Lung Metastases

scholarly journals Heterogeneous response to target therapy in metastatic papillary renal cell carcinoma evaluated by morphologic and metabolic multimodality imaging

Medicine ◽  
2019 ◽  
Vol 98 (50) ◽  
pp. e18093 ◽  
Author(s):  
Emanuele Naglieri ◽  
Artor Niccoli Asabella ◽  
Anna Giulia Nappi ◽  
Claudia Carella ◽  
Cristina Ferrari ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Multimodality Imaging ◽  
Target Therapy ◽  
Papillary Renal Cell Carcinoma

Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors

2007 ◽  
Vol 84 (4) ◽  
pp. 1114-1120 ◽  
Author(s):  
Jalal Assouad ◽  
Boriana Petkova ◽  
Pascal Berna ◽  
Antoine Dujon ◽  
Christophe Foucault ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Lung Metastases ◽  
Pathologic Findings

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.

1987 ◽  
Vol 5 (2) ◽  
pp. 286-291 ◽  
Author(s):  
H B Muss ◽  
J J Costanzi ◽  
R Leavitt ◽  
R D Williams ◽  
R A Kempf ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Lung Metastases ◽  
Response Duration ◽  
Complete Response ◽  
Recombinant Interferon ◽  
Routes Of Administration ◽  
Almost All

Ninety-seven patients with recurrent or metastatic renal cell carcinoma were randomized to receive recombinant interferon (IFN) alfa-2b (Intron A; Schering-Plough, Kenilworth, NJ) by either the subcutaneous (SC) or intravenous (IV) route. The SC dosage was 2 X 10(6) IU/m2 three times weekly, and the IV dose 30 X 10(6) IU/m2 for five consecutive days every 3 weeks. Dose escalation to a maximum of 10 X 10(6) IU/m2 SC and 50 X 10(6) IU/m2 IV was allowed for patients with minimal or absent toxicity. Five of 51 of the SC-treated patients (10%) and three of 46 of the IV-treated patients (7%) had a partial response (PR) or complete response (CR). Patients with prior nephrectomy, no prior treatment, and lack of bone metastases were most likely to respond, and a retrospective analysis of this subgroup revealed a 23% response rate. Achievement of response took from 3 weeks to 11 months, while response duration lasted from 3 to 31+ months. All responders had prior nephrectomy; six of eight had no prior chemotherapy or hormonal therapy; five had lung metastases, and none had bone metastases. Regardless of route, almost all patients developed a flu-like syndrome; however, grade 3 or greater toxicity was much more common for IV-treated patients. This trial demonstrates modest, but definite antitumor activity for recombinant interferon in advanced renal cell carcinoma. SC administration with lower dose and toxicity is as effective as treatment administered IV.

Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma

2020 ◽  
Vol 13 (7) ◽  
pp. e235177 ◽  
Author(s):  
Yukinori Harada ◽  
Shintaro Kakimoto ◽  
Taro Shimizu
Keyword(s):  
Renal Cell Carcinoma ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Lung Metastases ◽  
Soft Tissue Sarcomas ◽  
Positive Pressure ◽  
Non Invasive

Pazopanib is a multi-targeted tyrosine kinase inhibitor, which is indicated for use in patients with advanced renal cell carcinoma or advanced soft-tissue sarcomas. Although rare, interstitial lung disease has been reported as among the adverse sequelae of pazopanib therapy. We report the case of a 75-year-old man who developed interstitial lung disease during treatment with pazopanib for renal cell carcinoma with multiple lung metastases. The patient presented with dry cough and new-onset fatigue 3 months after initiation of pazopanib. He had mild hypoxia with bilateral ground-glass opacities on chest CT. He was treated with antibiotics for presumptive pneumonia, but his respiratory status rapidly deteriorated, and he required non-invasive positive pressure ventilation. He recovered on discontinuation of pazopanib and systemic steroids. Clinicians should recognise that interstitial lung disease can occur in patients who are undergoing treatment with pazopanib.

Sign in / Sign up

Export Citation Format

Share Document